Oncology and Hematology - Global Oncology Academy

433-448 of 612

Diving into New Directions of Radiopharmaceuticals
Diving into New Directions of Radiopharmaceuticals
Project Oncology®
Diving into New Directions of Radiopharmaceuticals
- Brianna Cagle
The Evolving AI Landscape in Nuclear Medicine
The Evolving AI Landscape in Nuclear Medicine
Project Oncology®
The Evolving AI Landscape in Nuclear Medicine
- Joyita Dutta
Highlighting the Current Status and Future of Theranostics
Highlighting the Current Status and Future of Theranostics
Project Oncology®
Highlighting the Current Status and Future of Theranostics
- Geoffrey B. Johnson, M.D., Ph.D.
A Look at the Horizon of Cancer Vaccines
A Look at the Horizon of Cancer Vaccines
Project Oncology®
A Look at the Horizon of Cancer Vaccines
- Lillian Siu, MD, FRCPC
A Unique Look at the Current and Future Directions of Cancer Vaccines
A Unique Look at the Current and Future Directions of Cancer Vaccines
Project Oncology®
A Unique Look at the Current and Future Directions of Cancer Vaccines
- Lillian Siu, MD, FRCPC
Updates on New Technologies and Imaging Agents in Healthcare
Updates on New Technologies and Imaging Agents in Healthcare
Project Oncology®
Updates on New Technologies and Imaging Agents in Healthcare
- Tyler J Bradshaw, PhD
The Power of Patient Advocacy in Daily Clinical Practice
The Power of Patient Advocacy in Daily Clinical Practice
Project Oncology®
The Power of Patient Advocacy in Daily Clinical Practice
- Ashley L. Sumrall, MD
The Impact of Advocacy on Healthcare
The Impact of Advocacy on Healthcare
Project Oncology®
The Impact of Advocacy on Healthcare
- Ashley L. Sumrall, MD
Targeting RET Alterations: Selpercatinib's Role in Pediatric Thyroid Cancer
Targeting RET Alterations: Selpercatinib's Role in Pediatric Thyroid Cancer
Project Oncology®
Targeting RET Alterations: Selpercatinib's Role in Pediatric Thyroid Cancer
Real-World Data on Treatment Choices for mccRCC
Real-World Data on Treatment Choices for mccRCC
Project Oncology®
Real-World Data on Treatment Choices for mccRCC
Thyroid Cancer and Gender-Affirming Hormone Therapy: Exploring a Potential Link
Thyroid Cancer and Gender-Affirming Hormone Therapy: Exploring a Potential Link
Project Oncology®
Thyroid Cancer and Gender-Affirming Hormone Therapy: Exploring a Potential Link
Nephrotoxicity in the Crosshairs: Optimizing Renal Cancer Care with Kidney Preservation
Nephrotoxicity in the Crosshairs: Optimizing Renal Cancer Care with Kidney Preservation
Project Oncology®
Nephrotoxicity in the Crosshairs: Optimizing Renal Cancer Care with Kidney Preservation
Hepatocellular Carcinoma: Examining Its Prevalence and Prognostic Biomarkers
Hepatocellular Carcinoma: Examining Its Prevalence and Prognostic Biomarkers
Project Oncology®
Hepatocellular Carcinoma: Examining Its Prevalence and Prognostic Biomarkers
Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
Project Oncology®
Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
Project Oncology®
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights
Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights
Project Oncology®
Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights
- Alan Bryce, MD

28/11